ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Approximately 15-20% of breast cancers (BC) exhibit ErbB-2 (also known as human epidermal growth factor receptor 2) membrane overexpression or gene amplification.
• ErbB-2-positive BC historically has a poor prognosis and increased metastatic potential, though targeted therapies have improved outcomes.
• Resistance to current ErbB-2-targeted therapies remains a significant clinical challenge.

Purpose of the Study:

• To review the non-canonical function of nuclear ErbB-2 in breast cancer.
• To elucidate the role of nuclear ErbB-2 in tumor growth, metastasis, and response to therapy.
• To highlight the potential of nuclear ErbB-2 as a biomarker and therapeutic target.

Main Methods:

• Literature review of studies investigating ErbB-2 localization and function in breast cancer cells.
• Analysis of evidence supporting nuclear ErbB-2's role as a transcriptional regulator.
• Synthesis of findings on the impact of nuclear ErbB-2 on breast cancer progression and treatment response.

Main Results:

• ErbB-2 is present in the nucleus of breast cancer cells, a finding known for over two decades.
• Nuclear ErbB-2 functions as a transcriptional regulator, influencing cellular processes.
• Understanding nuclear ErbB-2's actions is crucial for developing novel therapeutic strategies.

Conclusions:

• Nuclear ErbB-2 represents a critical, yet under-explored, aspect of ErbB-2-positive breast cancer.
• Targeting nuclear ErbB-2 may offer new avenues to overcome therapeutic resistance and improve patient outcomes.
• Further research into nuclear ErbB-2's mechanisms is warranted for its clinical application.